Literature DB >> 22550115

Rabies postexposure prophylaxis in routine practice in view of the new Centers for Disease Control and Prevention and World Health Organization recommendations.

Mediatrice Uwanyiligira1, Pierre Landry, Blaise Genton, Serge de Valliere.   

Abstract

BACKGROUND: New recommendations for rabies postexposure prophylaxis (PEP) were published by the Centers for Disease Control and Prevention and the World Health Organization in 2010. In view of these new recommendations, we investigated the adequacy of rabies PEP among patients consulting our travel clinic.
METHODS: A retrospective analysis of the files of all patients who consulted for rabies PEP at the Travel Clinic of the University Hospital in Lausanne, Switzerland, between January 2005 and August 2011 was conducted.
RESULTS: A total of 110 patients who received rabies PEP were identified. The median age of the patients was 34 years (range, 2-79 years), and 53% were women. Ninety subjects were potentially exposed to rabies while travelling abroad. Shortcomings in the management of these patients were (1) late initiation of rabies PEP in travelers who waited to seek medical care until returning to Switzerland, (2) administration of human rabies immunoglobulin (HRIG) to only 7 of 50 travelers (14%) who sought care abroad and for whom HRIG was indicated, and (3) antibody levels <0.5 IU/mL in 6 of 90 patients (6.7%) after 4 doses of vaccine.
CONCLUSIONS: Patients do not always receive optimal rabies PEP under real-life conditions. A significant proportion of patients did not develop adequate antibody levels after 4 doses of vaccine. These data indicate that the measurement of antibody levels on day 21 of the Essen PEP regimen is useful in order to verify an adequate immune response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22550115     DOI: 10.1093/cid/cis384

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  3 in total

1.  Enhanced transport of plant-produced rabies single-chain antibody-RVG peptide fusion protein across an in cellulo blood-brain barrier device.

Authors:  Waranyoo Phoolcharoen; Christophe Prehaud; Craig J van Dolleweerd; Leonard Both; Anaelle da Costa; Monique Lafon; Julian K-C Ma
Journal:  Plant Biotechnol J       Date:  2017-04-19       Impact factor: 9.803

2.  In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity.

Authors:  Waranyoo Phoolcharoen; Ashley C Banyard; Christophe Prehaud; David Selden; Guanghui Wu; Colin P D Birch; Tim H Szeto; Monique Lafon; Anthony R Fooks; Julian K-C Ma
Journal:  Vaccine       Date:  2018-03-06       Impact factor: 3.641

3.  Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial.

Authors:  Mark A Matson; Eran Schenker; Michal Stein; Vladislava Zamfirova; Huy-Binh Nguyen; Garrett E Bergman
Journal:  Hum Vaccin Immunother       Date:  2019-09-24       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.